公开(公告)号：US20230123268A1

公开(公告)日：2023-04-20

申请号：US18062892

申请日：2022-12-07

Applicant: Hoffmann-La Roche Inc.

Inventor： Angélica BEURIER ,  Luke GREEN ,  Christian KRAMER ,  Dmitry MAZUNIN ,  Emmanuel PINARD ,  Hasane RATNI

IPC: C07D487/04 ,  C07D471/04

Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3 and n are as defined herein, compositions including methods of making the compounds and using the compounds as ATX inhibitors.

公开(公告)号：US20230123178A1

公开(公告)日：2023-04-20

申请号：US17649321

申请日：2022-01-28

Applicant: Hoffmann-La Roche Inc.

Inventor： Claudia Ferrara Koller ,  Christina Claus ,  Christian Klein ,  Stefan Seeber ,  Maria Amann ,  Sandra Grau-Richards ,  Peter Bruenker ,  Pablo Umana ,  Viktor Levitski ,  Ekkehard Moessner

IPC: C07K16/28 ,  C07K14/705 ,  C12N15/62 ,  A61P35/00

Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules having at least one moiety capable of specific binding to PD1 and a first and a second polypeptide that are linked to each other by a disulfide bond, the first polypeptide having two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by a peptide linker and the second polypeptide having a single ectodomain of the same TNF ligand family member or a fragment thereof.

公开(公告)号：US20230122753A1

公开(公告)日：2023-04-20

申请号：US17822668

申请日：2022-08-26

Applicant: Hoffmann-La Roche Inc.

Inventor： Mads Aaboe JENSEN ,  Lars JOENSON ,  Gianluigi LICHINCHI ,  Jonas VIKESAA

IPC: C12N15/113 ,  A61P35/00

Abstract: The present invention relates to antisense oligonucleotides that are complementary to mammalian CD73 (NT5E) pre-mRNA, wherein the antisense oligonucleotides are capable of modulating the splicing of mammalian CD73 pre-mRNA exon 7. Splice modulation of mammalian CD73 exon 7 is beneficial for a range of medical disorders, including disorders in the field of immune-oncology.

公开(公告)号：US11622969B2

公开(公告)日：2023-04-11

申请号：US17739688

申请日：2022-05-09

Applicant: Hoffmann-La Roche Inc. ,  Chugai Seiyaku Kabushiki Kaisha

Inventor： Xiaoping Zhang ,  Kimio Terao

IPC: A61K39/395 ,  A61K31/573 ,  A61K38/47 ,  C07K16/28 ,  A61K9/00 ,  A61K39/00

Abstract: The present application concerns methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed.

公开(公告)号：US11618790B2

公开(公告)日：2023-04-04

申请号：US16704781

申请日：2019-12-05

Applicant: Hoffmann-La Roche Inc.

Inventor： Michael Gerg ,  Dieter Heindl ,  Gerhard Niederfellner ,  Wolfgang Schaefer ,  Michael Schraeml ,  Michael Tacke

IPC: C07K16/46 ,  C07K16/18 ,  C07K16/00 ,  C07K16/28 ,  C07K16/32 ,  G01N33/573 ,  G01N33/68 ,  A61K47/68

Abstract: Herein is reported a polypeptide-polynucleotide-complex as therapeutic agent and its use as tool for the targeted delivery of an effector moiety. The polynucleotide part of the complex is essentially resistant to proteolytic and enzymatic degradation in vivo. Additionally the polypeptide part specifically binds to a compound or structure such as a tissue or organ, a process or a disease. Thus, one aspect as reported herein is a polypeptide-polynucleotide-complex comprising a) a polypeptide specifically binding to a target and conjugated to a first member of a binding pair, b) a polynucleotide linker conjugated at its first terminus to the second member of the binding pair, and c) an effector moiety conjugated to a polynucleotide that is complementary to at least a part of the polynucleotide linker.

公开(公告)号：US11613587B2

公开(公告)日：2023-03-28

申请号：US16988540

申请日：2020-08-07

Applicant: Hoffmann-La Roche Inc.

Inventor： Christian Klein ,  Vaios Karanikas ,  Pablo Umana ,  Alfred Zippelius ,  Daniela Stefanie Thommen ,  Jens Schreiner

IPC: C07K16/00 ,  C07K16/30 ,  C07K16/28 ,  A61K47/68 ,  C07K16/46 ,  A61K39/00

Abstract: The present invention generally relates to T cell activating bispecific antigen binding molecules, PD-1 axis binding antagonists, and in particular to combination therapies employing such T cell activating bispecific antigen binding molecules and PD-1 axis binding antagonists, and their use of these combination therapies for the treatment of cancer.

公开(公告)号：US20230091561A1

公开(公告)日：2023-03-23

申请号：US17905121

申请日：2021-02-25

Applicant: Genentech, Inc. ,  Hoffmann-La Roche Inc.

Inventor： Hideki GARREN ,  Edmond Huatung TENG ,  Aurelien VIACCOZ ,  Hans-Christian VON BUEDINGEN

IPC: A61K31/519 ,  C07K16/28 ,  A61K9/20 ,  A61K9/48

Abstract: Provided herein are methods of treating Primary Progressive Multiple Sclerosis (PPMS) in a subject in need thereof, by administering to the subject about 200 mg of fenebrutinib twice daily, or an equivalent amount of a pharmaceutically acceptable salt thereof.

公开(公告)号：US20230087946A1

公开(公告)日：2023-03-23

申请号：US17620232

申请日：2020-06-19

Applicant: Hoffmann-La Roche Inc.

Inventor： Martin Robert EDELMANN ,  Thorsten MUSER

IPC: A61K51/04

Abstract: The invention comprises radiolabeled MOEM type oligonucleotide of the formula (I), (I) wherein n, X1, X2, the linker (1), the linker (2), Q* and the receptor targeting moiety are as defined (I) the description. The radiolabeled oligonucleotides of the formula (I) can be used for the determination of the biodistribution and pharmacokinetics of the oligonucleotide in the tissue or body fluid.

公开(公告)号：US20230081499A1

公开(公告)日：2023-03-16

申请号：US17992039

申请日：2022-11-22

Applicant: Hoffmann-La Roche Inc.

Inventor： Oliver POPP

IPC: C12N5/00 ,  C12N5/071

Abstract: The current invention reports the use of meta-tyrosine for increasing the specific productivity of a eukaryotic cell that produces/expresses a polypeptide. In the current method it is not necessary to perform a temperature-, osmolality- or pH shift or to add drugs like valproic acid or sodium butyrate to modulate the specific productivity of the cultivated cells. The method does not affect cell viability or product titer.

公开(公告)号：US11603411B2

公开(公告)日：2023-03-14

申请号：US15941524

申请日：2018-03-30

Applicant: Hoffmann-La Roche Inc.

Inventor： Harald Duerr ,  Sebastian Fenn ,  Ulrich Goepfert ,  Sabine Imhof-Jung ,  Christian Klein ,  Laurent Lariviere ,  Michael Molhoj ,  Joerg Thomas Regula ,  Petra Rueger ,  Wolfgang Schaefer

IPC: C07K16/28 ,  A61P25/00

Abstract: Herein are provided bispecific anti-human CD20/human transferrin receptor antibodies and methods of using the same.